A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma (original) (raw)

References

1. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD (2009) Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 3:353–367
   Article PubMed Google Scholar
2. Trevisani F, Cantarini MC, Wands JR, Bernardi M (2008) Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 29:1299–1305
   Article PubMed CAS Google Scholar
3. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972–1978
   Article PubMed Google Scholar
4. Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42(Suppl 3):S206–S214
   Article PubMed Google Scholar
5. Blonski W, Kotlyar DS, Forde KA (2010) Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 16:3603–3615
   Article PubMed Google Scholar
6. Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820–1832
   Article PubMed Google Scholar
7. Nugent C, Younossi ZM (2007) Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 4:432–441
   Article PubMed Google Scholar
8. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerkn G, Sym WK, Canbay A (2011) Nonalcoholic fatty liver disease progresses to HCC in the absence of apparent cirrhosis. Int J Cancer 128:2436–2443
   Article PubMed CAS Google Scholar
9. Leenders MW, Nijkamp MW, Borel Rinkes IH (2008) Mouse models in liver cancer research: a review of current literature. World J Gastroenterol 14:6915–6923
   Article PubMed CAS Google Scholar
10. Lin Y, Sun Z (2009) Current views on type 2 diabetes. J Endocrinol 204:1–11
    Article PubMed Google Scholar
11. Van Belle TL, Taylor P, von Herrath MG (2009) Mouse models for type 1 diabetes models. Drug Discov Today Dis 6:41–45
    Article Google Scholar
12. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T (2004) Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113:1774–1783
    PubMed CAS Google Scholar
13. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF (2004) Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287:G1035–G1043
    Article PubMed CAS Google Scholar
14. Anstee QM, Goldin RD (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87:1–16
    Article PubMed CAS Google Scholar
15. Larter CZ, Yeh MM (2008) Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23:1635–1648
    Article PubMed Google Scholar
16. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hsiao G, Subramaniam S, Berger NA, Croniger C, Lambris JD, Nadeau JH (2009) Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 18:2975–2988
    Article PubMed CAS Google Scholar
17. Yoneyama H, Harada A, Imai T, Baba M, Yoshie O, Zhang Y, Higashi H, Murai M, Asakura H, Matsushima K (1998) Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. J Clin Invest 102:1933–1941
    Article PubMed CAS Google Scholar
18. Yoneyama H, Matsuno K, Zhang Y, Murai M, Itakura M, Ishikawa S, Hasegawa G, Naito M, Asakura H, Matsushima K (2001) Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease. J Exp Med 193:35–49
    Article PubMed CAS Google Scholar
19. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321
    Article PubMed Google Scholar
20. Suzuki K, Sun X, Nagata M, Kawase T, Yamaguchi H, Sukumaran V, Kawauchi Y, Kawachi H, Nishino T, Watanabe K, Yoneyama H, Asakura H (2011) Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium. Pathol Int 61:228–238
    Article PubMed CAS Google Scholar
21. Tsujimoto T, Kawaratani H, Kitagawa T, Hirai T, Ohishi H, Kitade M, Yoshiji H, Uemura M, Fukui H (2008) Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model. World J Gastroenterol 14:6036–6043
    Article PubMed Google Scholar
22. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134–140
    Article PubMed Google Scholar
23. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231
    Article PubMed CAS Google Scholar
24. Lefkowitch JH (2005) Morphology of alcoholic liver disease. Clin Liver Dis 9:37–53
    Article PubMed Google Scholar
25. Iredale JP (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117:539–548
    Article PubMed CAS Google Scholar
26. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125:89–97
    Article PubMed CAS Google Scholar
27. Cadoret A, Ovejero C, Terris B, Souil E, Lévy L, Lamers WH, Kitajewski J, Kahn A, Parret C (2002) New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21:8293–8301
    Article PubMed CAS Google Scholar
28. Dal Bello B, Rosa L, Campanini N, Tinelli C, Torello Viera F, D’Ambrosio G, Rossi S, Sillni EM (2010) Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res 16:2157–2166
    Article PubMed CAS Google Scholar
29. Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Lu SN (2010) Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol 105:624–631
    Article PubMed Google Scholar
30. Davila JA (2010) Diabetes and hepatocellular carcinoma: what role does diabetes have in the presence of other known risk factors? Am J Gastroenterol 105:632–634
    Article PubMed Google Scholar
31. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801
    Article PubMed CAS Google Scholar
32. Rhodes CJ (2005) Type 2 diabetes—a matter of beta-cell life and death? Science 307:380–384
    Article PubMed CAS Google Scholar
33. Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118:829–838
    Article PubMed CAS Google Scholar
34. Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, Nishiguchi S, Inoue T, Naruko T, Ehara S, Kawada N, Arakawa T, Ueda M (2006) Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 43:506–514
    Article PubMed CAS Google Scholar
35. Fujii H, Ikura Y, Arimoto J, Sugioka K, Iezzoni JC, Park SH, Naruko T, Itabe H, Kawada N, Caldwell SH, Ueda M (2009) Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. J Atheroscler Thromb 16:893–901
    Article PubMed CAS Google Scholar
36. Gordon S (2007) Macrophage heterogeneity and tissue lipids. J Clin Invest 117:89–93
    Article PubMed CAS Google Scholar
37. Williams KJ, Feig JE, Fisher EA (2008) Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 5:91–102
    Article PubMed CAS Google Scholar
38. Tieu BC, Lee C, Sun H, Lejeune W, Recinos A 3rd, Ju X, Spratt H, Guo DC, Milewicz D, Tilton RG, Brasier AR (2009) An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest 119:3637–3651
    Article PubMed CAS Google Scholar
39. Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H, Ota T, Yokoyama M, Honda M, Miyamoto K, Kaneko S (2008) Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism 58:1071–1077
    Article Google Scholar
40. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121–124
    Article PubMed CAS Google Scholar
41. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S (1998) Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 351:725
    Article PubMed CAS Google Scholar

Download references